Clin Osteol 2013; 18(1): 16-21

Measures of adherence to therapy in patients with osteoporosisReview articles

Ládová K., Vytřískalová M., Vlček J.

Poor adherence to therapy is a widespread problem in the treatment of chronic diseases, particularly asymptomatic conditions. This risk may be eliminated, or at least controlled, by measuring the adherence. There are several methods which can evaluate objective and subjective parameters of the patient's approach to a treatment plan. Adherence to the therapy of osteoporosis is usually measured by indirect methods. Self-reports and pill counts, belonging to the simplest instruments, are easily applicable in clinical practice but there is a high risk of overestimation of the adherence. In the research of adherence to osteoporosis treatment, specific questionnaires on this metabolic disease seem to be very promising. Electronic monitoring is frequently considered a reference standard for indirect methods. Particularly the Medication Event Monitoring System can precisely assess adherence to current therapy by monitoring dates and times of drug administration. This has been successfully used, for example, in specific dosage regimes in antiresorptive therapy for osteoporosis. Pr ment of persistence. The article provides a description of the above indire in measuring adherence to the therapy of osteoporosis.

Keywords: adherence, compliance, persi porosis

Published: June 11, 2013  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Ládová K, Vytřískalová M, Vlček J. Measures of adherence to therapy in patients with osteoporosis. Osteologický bulletin. 2013;18(1):16-21.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Sabaté E. Adherence to long-term therapies. Eviden Organisation 2003. [online]. c2012 [cit. 2012-06-20]. family_planning/en/. http://www.who.int/topics/
    2. Cramer JA, Roy A, Burrell A et al. Medication compliance and persistence: t minology and definitions. Value Health. 2008;11:44-47. Go to original source...
    3. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005;353: 487-497. Go to original source...
    4. Vytřísalová M. Adherence k medikamentózni léčbě - známá neznámá. Remedia. 2009;19:225-230.
    5. Cadarette SM, Burden AM. Measuring and improving adherence to osteoporosis pharmacotherapy. Curr Opin Rheumatol 2010;22:397-403. Go to original source...
    6. Farmer KC. Methods for measuring and monitoring medication regimen adheren­ ce in clinical trials and clinical practice. Clin Ther 1999;21:1074-1090. Go to original source...
    7. Kothawala P, Badamgarav E, Ryu S, et al. Systematic review and meta-analysis real-world adherence to drug therapy for osteoporosis. Mayo Clin Proc 2007;82:1493-1501. Go to original source...
    8. Huybrechts KF, Ishak KJ, Caro JJ. Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone 2006;38: 922-928. Go to original source...
    9. Imaz I, Zegarra P, González-Enríquez J et al. Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and metalysis. Osteoporos Int 2010;21:1943-1951. Go to original source...
    10. Ingerski LM, Hente EA, Modi AC et al. Electronic measurement of medication adherenc 528-534.
    11. van den Boogaard J, Lyimo RA, Boeree MJ et al. Electronic monitoring of tre ment adherence and validation of alternative adherence measures in tuberculosis patients: a pilot study. Bull World Health Organ 2011;89:632-639. Go to original source...
    12. Muller AD, Jaspan HB, Myer L et al. Standard measures are inadequate to tor pediatric adherence in a resource-limited setting. AIDS Behav 2011; 15: 422-431. Go to original source...
    13. Shi L, Liu J, Koleva Y et al. Concordance of adherence measureme reported adherence questionnaires and medication monitoring devices. Pharmacoeconomics 2010;28:1097-1107. Go to original source...
    14. De Bleser L, De Geest S, Vandenbroeck S et al. How accurate are electronic nitoring devices? A laboratory study testing two devices to measure medication adherence. Sensors (Basel) 2010;10:1652-1660. Go to original source...
    15. Delmas PD, Vrijens B, Eastell R et al. Effect of monitoring bone turnover mark on persistence with risedronate treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab 2007;92:1296-1304. Go to original source...
    16. Kendler DL, Ringe JD, Ste-Marie LG et al. Risedronate dosing before breakfast compared with dosing later in the day in women with postmenopausal osteoporo­ sis. Osteoporos Int 2009;20:1895-1902. Go to original source...
    17. Kendler DL, McClung MR, Freemantle N et al. Adherence, preference, and satis­ faction of postmenopausal women taking denosumab or alendronate. Osteoporos Int 2011;22:1725-1735. Go to original source...
    18. Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self­ reported measure of medication adherence. Med Care 1986;24:67-74. Go to original source...
    19. Morisky DE, Ang A, Krousel-Wood M, Ward HJ. Predictive validity of a medica­ tion adherence measure in an outpatient setting. J Clin Hypertens (Greenwich) 2008;10:348-354. Go to original source...
    20. Svarstad BL, Chewning BA, Sleath BL, Claesson C. The Brief Medication Questionnaire: a tool for screening patient adherence and barriers to adherence. Patient Educ Couns 1999;37:113-124. Go to original source...
    21. Ajzen I. The theory of planned behaviour: reactions and reflections. Psychol Health 2011;26:1113-1127. Go to original source...
    22. Garber MC, Nau DP, Erickson SR et al. The concordance of self-report with ot­ her measures of medication adherence: a summary of the literature. Med Care 2004;42:649-652. Go to original source...
    23. Breuil V, Cortet B, Cotté FE et al. Validation of the adherence evaluation of oporosis treatment (ADEOS) questionnaire for osteoporotic post-menopausal wo­ men. Osteoporos Int 2012;23:445-455. Go to original source...
    24. Reynolds K, Viswanathan HN, O'Malley CD et al. Psychometric properties of the Osteoporosis-specific Morisky Medication Adherence Scale in postmenopausal women with osteoporosis newly treated with bisphosphonates. Ann Pharmacother 2012;46:659-670. Go to original source...
    25. Berg KM, Arnsten JH. Practical and conceptual challenges in measuring antire­ troviral adherence. J Acquir Immune Defic Syndr 2006;43, Suppl 1:S79-87. Go to original source...
    26. Spoelstra SL, Given CW. Assessment and measurement of adherence to oral anti­ neoplastic agents. Semin Oncol Nurs 2011;27:116-132. Go to original source...
    27. Netelenbos JC, Geusens PP, Ypma G et al. Adherence and profile of non-persistence in patients treated for osteoporosis-a large-scale, long-term retrospective study in The Netherlands. Osteoporos Int 2011;22:1537-1546. Go to original source...
    28. Cotté FE, Fardellone P, Mercier F, et al. Adherence to monthly and weekly oral bisphosphonates in women with osteoporosis. Osteoporos Int 2010;21:145-155. Go to original source...
    29. Ziller V, Kostev K, Kyvernitakis I et al. Persistence and compliance of medicat used in the treatment of osteoporosis-analysis using a large scale, representative, longitudinal German database. Int J Clin Pharmacol Ther 2012;50:315-322. Go to original source...
    30. Kanis JA, Cooper C, Hiligsmann M et al. Partial adherence: a new perspective on health economic assessment in osteoporosis. Osteoporos Int 2011;22:2565-2573. Go to original source...
    31. Dezii CM. Persistence with drug therapy: a practical approach using administ ve claims data. Manag Care 2001;10:42-45.
    32. Informace pro pacienty a zdravotníky. SUKL. [online]. c2012 [cit. 2012-9-27]. http://www.sukl.cz/leciva/informace-pro-pacienty-a-zdravotnicke-pracovniky.

    Return to the content


    Clinical Osteology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.